Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (40)

I-03Sulav Duwal

Top-down and Bottom-Up modelling approaches in Systems Pharmacology: Understanding clinical efficacy of NRTIs against HIV-1

Wednesday 10:20-11:40

I-04Lisa Ehmann

Pharmacokinetics of meropenem in critically ill patients with varying renal function

Wednesday 10:20-11:40

I-10Natalie Filmann

Comparing the individual and the population approach in fitting heterogeneous PK/PD data of patients with chronic hepatitis B after liver transplantation

Wednesday 10:20-11:40

I-19

PK/PD Modeling of Tuberculosis for Identification of Biomarkers Associated with Treatment Duration

Wednesday 10:20-11:40

I-41Christoph Hethey

Impact of the intracellular ribosomal concentration on in vitro bacterial growth kinetics and the antibacterial effect of linezolid on S. aureus in time-kill assays

Wednesday 10:20-11:40

I-43Eef Hoeben

Viral Kinetic Modeling of HCV RNA Decline during Treatment with Simeprevir in Combination with Sofosbuvir

Wednesday 10:20-11:40

I-52Swati Jaiswal

Pharmacokinetic-Pharmacodynamic modeling of miltefosine in Leishmania donovani infected Golden Syrian Hamsters

Wednesday 10:20-11:40

I-62

Population pharmacokinetics of plasma and intracellular miltefosine concentrations in cutaneous leishmaniasis patients

Wednesday 10:20-11:40

I-70

Mathematical modeling and systems pharmacology of tuberculosis therapy with isoniazid

Wednesday 10:20-11:40

II-06

Population pharmacokinetics of the amodiaquine: pooling data across different studies to optimize dosing in neglected populations

Wednesday 15:10-16:30

II-11Manel Aouri

Population pharmacokinetics analysis of dolutegravir in HIV-1 infected individuals

Wednesday 15:10-16:30

II-16

Population pharmacokinetics analysis of elvitegravir and cobicistat in HIV-1 infected individuals

Wednesday 15:10-16:30

II-18Ana Bastos

Using modeling and simulation to design and evaluate dosing strategies for temocillin in haemodialysis patients

Wednesday 15:10-16:30

II-24Dimitra Bon

PK-PD-VK modeling for hepatitis C treatment with the CI and Generalized multiscale model.

Wednesday 15:10-16:30

II-30Margreke Brill

Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis

Wednesday 15:10-16:30

II-34Charles Burdet

Joint modeling of plasma and fecal moxifloxacin pharmacokinetics in healthy volunteers

Wednesday 15:10-16:30

II-44Chunli Chen

Assessment of Pharmacodynamic Interactions in the Mycobacteria Tuberculosis Infected Mouse using The Multistate Tuberculosis Pharmacometric Model and the General Pharmacodynamic Interaction Model

Wednesday 15:10-16:30

II-50Oskar Clewe

Pre-clinical Susceptibility Characterization and Pharmacodynamic Interaction Assessment Using the Multistate Tuberculosis Pharmacometric Model

Wednesday 15:10-16:30

II-66Amelia Deitchman

Tetracycline against Pseudomonas aeruginosa: Pharmacokinetic/Pharmacodynamic Modeling of In Vitro Time-Kill Curves

Wednesday 15:10-16:30

II-69Paolo Denti

Population Pharmacokinetics of Levofloxacin in South African children.

Wednesday 15:10-16:30

II-72Thomas Dorlo

Translational PKPD modeling framework to assess the predictive performance of a preclinical visceral leishmaniasis hamster model

Wednesday 15:10-16:30

III-05

Population pharmacokinetic and pharmacodynamic (PK/PD) modelling of emerging artemisinin resistance in Southern Myanmar

Thursday 10:05-11:30

III-10Vincent Madelain

Favipiravir pharmacokinetics in non-human primates: insights for future efficacy studies against hemorrhagic fever viruses

Thursday 10:05-11:30

III-15Ben Margetts

Modelling Severe Human Cytomegalovirus Infections in an Immunocompromised Paediatric Patient Population

Thursday 10:05-11:30

III-17Lisa Martial

Population PK model and pharmacokinetic target attainment of micafungin in ICU patients

Thursday 10:05-11:30

III-38Per Olsson Gisleskog

Predicting the effects of combining broadly neutralizing antibodies (bNabs) binding to different HIV viral epitopes

Thursday 10:05-11:30

III-49Carlos Perez-Ruixo

Population pharmacokinetics and antiviral efficacy in neonatal lambs: evidence of rapid maturation and auto-induction drug effect in metabolic clearance

Thursday 10:05-11:30

III-54

Population Pharmacokinetics of the Novel Antimalarial OZ439

Thursday 10:05-11:30

III-62Rachel Rose

Development of a novel multi-compartment granuloma model to predict local drug distribution and its impact on pharmacodynamics and disease progression in tuberculosis.

Thursday 10:05-11:30

III-67Sophie Rhodes

Previous BCG vaccination associated with variation in Mycobacterial-specific immune response: a modelling study

Thursday 10:05-11:30

III-70Clémence Rigaux

Parasitemia clearance modeling following Ferroquine administration in P. Falciparum infected patients

Thursday 10:05-11:30

IV-13Amaia Soraluce

Population pharmacokinetics of linezolid in critically ill patients and treatment probability of target attainment

Thursday 14:40-16:00

IV-17M. Elena Suarez Gonzalez

How delayed or missed doses influence efficacy of amoxicillin in outpatients with community-acquired pneumonia: A pharmacokinetic/pharmacodynamic simulation analysis

Thursday 14:40-16:00

IV-19Robin Svensson

Population pharmacokinetic modeling to assess the non-linear increase in exposure following increasing doses of rifampicin

Thursday 14:40-16:00

IV-28Anders Thorsted

Toxicokinetics of Endotoxin and its Induction of Pro-Inflammatory Cytokines Tumor Necrosis Factor a and Interleukin-6

Thursday 14:40-16:00

IV-32Bruna Gaelzer Silva Torres

Population Pharmacokinetic Modeling of Ciprofloxacin Free Lung Concentrations in Healthy and Pseudomonas aeruginosa Biofilm Infected Wistar Rats

Thursday 14:40-16:00

IV-40Muhammad Usman

Population Pharmacokinetics of Meropenem in Elderly Patients: Dosing simulations based on Renal Function

Thursday 14:40-16:00

IV-50Max von Kleist

Systems pharmacology pipeline to assess NRTI-efficacy for repurposing as pre-exposure prophylactic compounds against HIV-1 infection

Thursday 14:40-16:00

IV-61Rixt Wijma

Population pharmacokinetics of meropenem during intermittent and continuous infusion in healthy volunteers

Thursday 14:40-16:00

IV-75Chenguang Zhou

Semi-mechanistic multiple-analyte pharmacokinetic model for a THIOMAB antibiotic conjugate against Staphylococcus aureus in mouse, rat and monkey

Thursday 14:40-16:00